loading...| Preferred Name |
pimavanserin |
|
| Synonyms |
ACP-103 |
|
| ID |
http://purl.bioontology.org/ontology/MESH/C510793 |
|
| altLabel |
ACP-103 Nuplazid bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate ACP 103 pimavanserin tartrate urea, n-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide ACP103 |
|
| cui |
C4238587 C1722267 C1722268 C2607621 |
|
| Has mapping qualifier | ||
| HM |
D010880 D014508/Q000031 |
|
| Inverse of RB |
NA83F1SJSR JZ963P0DIK |
|
| isa |
http://purl.bioontology.org/ontology/MESH/D000978 |
|
| LT |
TRD |
|
| Mapped to | ||
| MDA |
20060607 |
|
| MeSH Frequency |
155 |
|
| MMR |
20181115 |
|
| notation |
C510793 |
|
| PA |
D000978 D058830 D014150 |
|
| prefLabel |
pimavanserin |
|
| RR |
NA83F1SJSR |
|
| SC |
1 |
|
| Scope Statement |
A 5-HT(2A) inverse agonist; ACP-103 is the dihydroxybutanedioate (2:1) salt. It is used to treat hallucinations and delusions associated with PARKINSON DISEASE; structure in first source. |
|
| SRC |
J Pharmacol Exp Ther 2006 May;317(2):910-8 |
|
| TERMUI |
T675510 T675511 T000908856 T000908855 T675512 T675509 T000908604 T000908857 T734647 |
|
| TH |
NLM (2009) FDA SRS (2013) USAN (19XX) INN (19XX) NLM (2013) NLM (2006) NLM (2017) |
|
| tui |
T109 T121 |